Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 6/20 | 0.66 |
| ▸ | CYP2C19 | P33261 | 6/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.66 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.66 |
| ▸ | TSHR | P16473 | 1/20 | 0.66 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.61 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | KCNA5 | P22460 | 4/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.57 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8074161 | 1.00 | CYP1A2 (0.66) | CYP1A2CYP2C19CYP3A4CYP2D6TSHR | |
| SCHEMBL13039159 | 1.00 | CYP1A2 (0.66) | CYP1A2CYP2C19CYP3A4CYP2D6TSHR | |
| SCHEMBL3583059 | 0.98 | OPRL1 (0.63) | CYP1A2CYP2C19CYP3A4CYP2D6TSHR | |
| SCHEMBL1205831 | 0.98 | OPRL1 (0.63) | CYP1A2CYP2C19CYP3A4CYP2D6TSHR | |
| SCHEMBL8507420 | 0.98 | OPRL1 (0.63) | CYP1A2CYP2C19CYP3A4CYP2D6TSHR | |
| SCHEMBL11702651 | 0.83 | OPRL1 (0.49) | CYP1A2CYP2C19CYP3A4CYP2D6TSHR | |
| SCHEMBL15546040 | 0.81 | CYP1A2 (0.45) | CYP1A2CYP2C19CYP3A4CYP2D6TSHR | |
| SCHEMBL14035499 | 0.81 | SLC6A4 (0.68) | CYP1A2CYP2C19CYP2D6CYP2C9OPRL1 | |
| SCHEMBL3838999 | 0.81 | CYP1A2 (0.45) | CYP1A2CYP2C19CYP3A4CYP2D6TSHR | |
| SCHEMBL5139722 | 0.81 | SLC6A4 (0.68) | CYP1A2CYP2C19CYP2D6CYP2C9OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240245670-A1 | DOSING REGIMEN AND PHARMACEUTICAL COMBINATION COMPRISING 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES | NOVARTIS AG (CH) | 2024-07-25 | — | — | US | disclosed |
| EP-0789021-B1 | Hydroxamic acid compounds as opioid kappa receptor agonists | PFIZER (US) | 2000-10-11 | — | — | EP | disclosed |
| US-5837717-A | ANALGESICS, ANTIINFLAMMATORY AGENTS, ANTITUSSIVE AGENTS, DIURETICS, NEUROPROTECTIVE AGENTS; TREATING BOWEL DISEASE SUCH AS ABDOMINAL PAIN | PFIZER INC. (US) | 1998-11-17 | — | — | US | disclosed |
| EP-0789021-A1 | Hydroxamic acid compounds as opioid kappa receptor agonists | PFIZER INC. (US) | 1997-08-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240245670-A1 | DOSING REGIMEN AND PHARMACEUTICAL COMBINATION COMPRISING 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES | IKZF1, IKZF2, IKZF3 | CYP1A2 2248/4885CYP2C19 4015/4885CYP3A4 1376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.